Anjali Sheth, MD
Glaucoma Specialist · Longmont, CONPI 1780908608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Alcon at 30.8% of the total.
Across 131 payments — averaging $31.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$176
- Bausch & Lomb Americas Inc.$171
- Omeros Corporation$157
- Harrow Eye, LLC$130
- plus $974 from 21 others
What the payments were for
- Food & beverage$4,03198%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 27 | $1,264 |
| AbbVie(2 entities) | 45 | $1,235 |
| Regeneron Healthcare Solutions, Inc. | 7 | $176 |
| Bausch & Lomb Americas Inc. | 8 | $171 |
| Omeros Corporation | 2 | $157 |
| Harrow Eye, LLC | 2 | $130 |
| Rxsight Inc | 4 | $113 |
| Aerie Pharmaceuticals, Inc. | 3 | $100 |
| Glaukos Corporation | 4 | $91 |
| Mallinckrodt Hospital Products Inc. | 4 | $84 |
| Sight Sciences, Inc. | 1 | $83 |
| Apellis Pharmaceuticals, Inc. | 3 | $70 |
| Coherus Oncology, Inc. | 3 | $66 |
| NEW World Medical,inc. | 1 | $56 |
| Amgen(2 entities) | 2 | $46 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $35 |
| Astellas Pharma US Inc | 1 | $27 |
| Eyevance Pharmaceuticals LLC | 2 | $23 |
| Nova Eye, Inc. | 1 | $23 |
| Rayner Intraocular Lenses Limited | 1 | $21 |
| Iridex Corporation | 1 | $20 |
| Genentech, Inc. | 1 | $17 |
| Spark Therapeutics, Inc. | 1 | $16 |
| Tarsus Pharmaceuticals, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Ivantis, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$408
- XEN GLAUCOMA TREATMENT SYSTEM$338
- Hydrus Microstent$134
- OMIDRIA$125
- DURYSTA$116
- SIMBRINZA$116
- Rhopressa$116
- Rocklatan$116
- VEVYE$116
How this compares
Too few glaucoma specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 115 | $81,981 |
| VyzultaLatanoprostene Bunod | 66 | $34,834 |
| RhopressaNetarsudil Mesylate | 54 | $32,756 |
| Alphagan PBrimonidine Tartrate | 29 | $23,532 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $20,744 |
| XiidraLifitegrast | 14 | $19,079 |
| Prednisolone Acetate | 343 | $18,589 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $16,198 |
| Latanoprost | 744 | $11,363 |
| Travoprost | 47 | $10,963 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 478 | $8,889 |
| Timolol Maleate | 728 | $8,058 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $6,669 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $5,320 |
| Brimonidine Tartrate | 423 | $4,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan | $1,235 | $121,711173 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $171 | $53,91380 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $100 | $53,49983 claims |
| AlconSimbrinza | $1,264 | $6,66919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Longmont
- Micah RothsteinLongmont$5K
- Mansi ParikhLongmont$3K
- Malik KahookAurora$1.3M
- Leonard SeiboldAurora$41K
- Stephanie MuylaertLittleton$17K
- Monica ErtelAurora$7K
- Jeffrey SoohooAurora$5K
- Kent BashfordFort Collins$5K
- Ameay NaravaneLittleton$3K
- Cameron ClarkeDurango$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.